On April 5, 2021 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported a poster presentation on safety and tolerability of twice daily administered poziotinib in patients with EGFR or HER2 exon 20 mutations (Press release, Spectrum Pharmaceuticals, APR 5, 2021, View Source [SID1234577580]). The company will also present a poster on the evaluation of same-day dosing of ROLONTIS (eflapegrastim) in neutropenic rats and patients with early-stage breast cancer. These poster presentations will be available at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting, taking place from April 10-15, 2021. Details of the presentations are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutations
Speaker: Xiuning Le, M.D., Ph.D.
Session: PO.CT02 – Phase 2 Clinical Trials
Date and Time: April 10, 2021 from 8:30 am – 11:59 pm ET
Presentation Number: CT169

Title: Same-day administration of Eflapegrastim with chemotherapy enhances neutropenic recovery in neutropenic rats and in early-stage breast cancer patients
Speaker: John A. Barrett
Session: PO.CT01 – Phase 1 Clinical Trials
Date and Time: April 10, 2021 from 8:30 am – 11:59 pm ET
Presentation Number: CT116

The poster presentations will be available for viewing by registered participants during the conference via the AACR (Free AACR Whitepaper) website on April 10, 2021.